New Publication: Automated tumor immunophenotyping predicts clinical benefit from anti-PD-L1 immunotherapy
Home
>
Science Hub
>
New Publication:
Automated tumor immunophenotyping predicts clinical benefit from anti-PD-L1 immunotherapy
April 11, 2024
Hartmut Koeppen et al. The Journal of Pathology
Automated tumor immunophenotyping predicts clinical benefit from anti-PD-L1 immunotherapy
You might also be interested by
News
CellCarta Secures Global Exclusivity for Biofidelity's Aspyre® Lung to Advance Targeted Lung Cancer Testing
March 18, 2026
More infoPosters
Validation of an ultra-sensitive assay for biomarker testing in NSCLC patients as Clinical Trial Assay (CTA)
March 3, 2026
More info